Discovery finally wins US FDA's blessing for preemie lung drug
This article was originally published in Scrip
A cumulative sigh of relief from investors blew shares of Discovery Laboratories as high as 37% in after-hours trading on 6 March on word that the US FDA finally approved the company's humanised surfactant Surfaxin (lucinactant) as a preventive therapy for respiratory distress syndrome (RDS) in premature infants.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.